Missing: AkaRx's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: AkaRx's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing AkaRx
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
AkaRx is included in 1 Expert Collection, including Biopharma Tech.
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Latest AkaRx News
May 23, 2018
The information provided by BioPortfolio.com is not a substitute for professional medical advice, diagnosis or treatment. The BioPortfolio site is sponsored BioPortfolio Limited with offices at Stafford House, 10 Prince of Wales Road, Dorchester, DT1 1PW, England. If you are a legal copyright holder or a designated agent for such and you believe a post on this website falls outside the boundaries of “Fair Use” and legitimately infringes on your or your client's copyright we may be contacted concerning copyright matters here: Contact BioPortfolio . All rights reserved. All other trademarks recognized. Copyright © 1997-2018 BioPortfolio Limited. Site developed by Alacrify Ltd .
AkaRx Frequently Asked Questions (FAQ)
When was AkaRx founded?
AkaRx was founded in 2005.
Where is AkaRx's headquarters?
AkaRx's headquarters is located at Mack Centre IV, Paramus.
What is AkaRx's latest funding round?
AkaRx's latest funding round is Acq - Fin.
How much did AkaRx raise?
AkaRx raised a total of $12.5M.
Who are the investors of AkaRx?
Investors of AkaRx include PBM Capital Group, Eisai, InterWest Partners, Sutter Hill Ventures and Astellas Venture Management.
Who are AkaRx's competitors?
Competitors of AkaRx include Unither Pharmaceuticals, OcuNexus Therapeutics, Aegerion Pharmaceuticals, NextWave Pharmaceuticals, Omthera Pharmaceuticals and 13 more.
Compare AkaRx to Competitors
ENTRA Pharmaceuticals is a specialty pharmaceutical company developing therapies and improving existing treatments in areas with high unmet medical needs. In addition to the company's technology platform, ENTRA possesses strong expertise in preclinical and clinical drug development and commercialization.
Savior Lifetec is engaged in the development & manufacture of high quality sterile API (Active Pharmaceutical Ingredients) especially carbapenem antibiotics for generic drug markets.
IVREA Pharmaceuticals is a specialty pharmaceutical company focused on clinical development and commercialization of novel prescription pharmaceuticals for the treatment of dermatologic conditions. IVREA's pharmaceuticals leverage topical delivery technologies.
GeneraMedix Inc. is a pharmaceutical company that develops, markets and distributes generic injectable products. nnThe company's MissionnnThe company aims to bring to market generic products where the active pharmaceutical ingredient is difficult to source, manufacturing or regulatory hurdles exist and are difficult to overcome, or where product is in short supply. n
United Biomedical operates as a biopharmaceutical company. The Company develops immunotherapeutics and vaccines for chronic and infectious diseases.
Grand River Aseptic Pharmaceutical Packaging is a pharmaceutical contract manufacturing organization (CMO) supporting the rapid development of new biomedicines to the clinical stage in the State of Michigan. Grand River APP is the result of an alliance between Van Andel Institute (www.vai.org) and Grand Valley State University, and is operating as a non-profit, state- and federally funded corporation. Grand River APP's first aims to assure that therapeutics are properly distributed into dosage forms for all-important Phase I and Phase II human clinical trials. This process, Fill/Finish and Lyophilization, will be offered broadly to academic, nonprofit, and for-profit organizations in Michigan and across North America for liquid-based drug candidates that require vialing in an FDA-regulated aseptic clean room environment. Typical products envisioned for Grand River APP services include small molecule drugs, peptides, monoclonal antibodies, therapeutic proteins and nano-medicines. As a consequence, however, Grand River APP cannot process cytotoxic/genotoxic or virally-based candidates (e.g. viral vaccines).
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.